Gut Liver.
2021 Sep;15(5):641-642. 10.5009/gnl210345.
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
- 3Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2520115
- DOI: http://doi.org/10.5009/gnl210345
Abstract
- No abstract available
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Biological Therapy for Inflammatory Bowel Disease in Children
- Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
- Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease
- Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
- Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease
